MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test

Envisia (Veracyte) genomic classifier is covered for patients with interstitial lung disease who are suspected of having idiopathic pulmonary fibrosis when HRCT does not show a definitive UIP pattern and there is no known cause of ILD. The test must be performed on bronchoscopy transbronchial biopsy (TBB) tissue samples and is intended to provide a categorical UIP versus non-UIP result to help guide management and potentially avoid surgical lung biopsy; consideration is emphasized for patients older than 60 with indeterminate HRCT.

"Envisia testing is covered for patients with interstitial lung disease (suspected idiopathic pulmonary fibrosis) who do not have a definitive usual interstitial pneumonia (UIP) pattern on high-reso..."

Sign up to see full coverage criteria, indications, and limitations.